Teprotumumab ELISA Kit,96T,DY353058-96T,Abinscience

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant human IGF1R antigen has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Teprotumumab in the sample competitively binds to the pre-coated protein with biotin-labeled Teprotumumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Teprotumumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Stability and Storage	When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.
Detection method	Colorimetric
Sample type	Plasma, Serum
Assay type	Quantitative
Sensitivity
Range	62.5 ng/mL - 4,000 ng/mL
Recovery	80-120%
Background	Teprotumumab is a human IgG1 monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) that is used in the therapy of Graves ophthalmopathy (thyroid eye disease). Graves disease is an autoimmune disease associated with autoantibodies, hyperthyroidism and a distinctive form of eye disease marked by ocular inflammation and proptosis causing eye pain, dryness, redness, and swelling which if severe can cause diplopia (double-vision) and loss of vision. Graves ophthalmopathy is associated with autoantibodies to thyrotropin and hypertrophy of ocular fibroblasts which overexpress the IGF1 receptor. Teprotumumab causes inhibition of IGF1 binding to its receptor and preventing cell activation. IGF1 is a potent modulator of cell growth and inhibitor of programmed cell death, acting via the PI3K-AKT-mTOR pathway. The inhibition of IGF1 signaling decreases fibroblast proliferation and hypertrophy.
Alternative Names	RO4858696-000, CAS: 1036734-93-6
Shipping	2-8 ℃
Specifications	Teprotumumab
Note	For Research Use Only.